7 reports of this reaction
1.2% of all GLYBURIDE AND METFORMIN HYDROCHLORIDE reports
#19 most reported adverse reaction
CORONARY ARTERY DISEASE is the #19 most commonly reported adverse reaction for GLYBURIDE AND METFORMIN HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 7 FDA adverse event reports linking GLYBURIDE AND METFORMIN HYDROCHLORIDE to CORONARY ARTERY DISEASE. This represents approximately 1.2% of all 579 adverse event reports for this drug.
GLYBURIDE AND METFORMIN HYDROCHLORIDE has an overall safety score of 72 out of 100. Patients taking GLYBURIDE AND METFORMIN HYDROCHLORIDE who experience coronary artery disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CORONARY ARTERY DISEASE is a less commonly reported adverse event for GLYBURIDE AND METFORMIN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to coronary artery disease, the following adverse reactions have been reported for GLYBURIDE AND METFORMIN HYDROCHLORIDE:
The following drugs have also been linked to coronary artery disease in FDA adverse event reports:
CORONARY ARTERY DISEASE has been reported as an adverse event in 7 FDA reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CORONARY ARTERY DISEASE accounts for approximately 1.2% of all adverse event reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE, making it a notable side effect.
If you experience coronary artery disease while taking GLYBURIDE AND METFORMIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.